A rare complication of ulcerative colitis in children: Pyoderma gangrenosum

Öz

Pyoderma gangrenosum (PG) is a rare inflammatory skin disease mainly characterized by ulcers. More than half of the PG is associated with systemic diseases like inflammatory bowel disease. About 4% of PG is seen during childhood. Here we report a 12-year-old girl presented with fever and bloody diarrhea and who developed a painful leg ulcer during follow up period and diagnosed as ulcerative colitis.

Anahtar Kelimeler

• Ulcerative colitis,Pyoderma gangrenosum,Children

Çocuklarda ülseratif kolitin nadir bir komplikasyonu: Piyoderma gangrenozum

Öz

Piyoderma gangrenozum (PG), esas olarak ülserlerle karakterize nadir görülen bir inflamatuar deri hastalığıdır. PG’nin yarısından fazlası, inflamatuar bağırsak hastalığı gibi sistemik hastalıklarla ilişkilidir. Olguların yaklaşık %4’ü çocukluk döneminde görülür. Burada ateş ve kanlı ishal ile başvuran, takip döneminde ağrılı bacak ülseri gelişen ve ülseratif kolit tanısı konulan 12 yaşında bir kız hastayı sunuyoruz.

Anahtar Kelimeler

• ülseratif kolit,piyoderma gangrenozum,çocuklar

Kaynakça

1. 1. Arguelles-Arias F, Castro-Laria L, Lobaton T, et al. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci 2013;58:2949-54.
2. 2. Soleimani T, Sasor SE, Spera L, et al. Pediatric pyoderma gangrenosum: is it just big wounds on little adults? J Surg Res 2016;206:113-7.
3. 3. Kechichian E, Haber R, Mourad N, et al. Pediatric pyoderma gangrenosum: a systematic review and update. Int J Dermatol 2017;56:486-95.
4. 4. Bissonnette C, Kauzman A, Mainville GN. Oral pyoderma gangrenosum: diagnosis, treatment and challenges: a systematic review. Head Neck Pathol 2017;11:427-41.
5. 5. Niu R, Zheng J, Ding D, et al. Giant pyoderma gangrenosum in a patient with ulcerative colitis: A case report. Medicine (Baltimore) 2020;99:e18795.
6. 6. Zampeli VA, Lippert U, Nikolakis G, et al. Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare.Treatment with infliximab. J Dermatol Case Rep 2015;9:62-6.
7. 7. Brooklyn T, Dunnill MG, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006;22:181-4.
8. 8. Miller J, Yentzer BA, Clark A, et al. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 2010;62:646-54.

9. 9. Wollina U. Pyoderma gangrenosum: a review. Orphanet J Rare Dis 2007;15:1-8.
10. 10. Futami H, Kodaira M, Furuta T, et al. Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and cyclosporine. J Gastroenterol 1998;33:408-11.
11. 11. Powell RJ, Holbrook MR, Stevens A. Pyoderma gangrenosum and its treatment. Lancet 1997;350:1720-1.
12. 12. Gettler S, Rothe M, Grin C, et al. Optimal treatment of pyoderma gangrenosum. Am J Clin Dermatol 2003;4:597-608.
13. 13. Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003;98:1821-6.
14. 14. Kim TY, Han DS, Eun CS, et al. Recombinant human epidermal growth factor enhances wound healing of pyoderma gangrenosum in a patient with ulcerative colitis. Inflamm Bowel Dis 2008;14:725-7.
15. 15. Charles CA, Leon A, Banta MR, et al. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol 2007;46:1095-9.
16. 16. Fahmy M, Ramamoorthy S, Hata T, et al. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol 2012;107:794-5.
17. 17. Brenner M, Ruzicka T, Plewig G, et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009;161:1199-201.
18. 18. Geusau A, Mothes-Luksch N, Nahavandi H et al. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol 2013;149:209-15.